MedTrace Logo

A Phase 1 Study of BHV-1530 in Advanced Solid Tumors

NCT06874335 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2026-05-13

No results posted yet for this study

Summary

This is a Phase 1, first in human (FIH), open-label, multicenter study of BHV-1530 in adult participants with advanced or metastatic solid tumors.

Conditions

Interventions

DRUG

BHV-1530

BHV-1530 will be administered as an IV infusion on Day 1 of each 21-day cycle

Sponsors & Collaborators

  • Biohaven Therapeutics Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-20
Primary Completion
2029-03-31
Completion
2029-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06874335 on ClinicalTrials.gov